The FDA has approved two fast tests for the coronavirus that is causing the COVID-19 epidemic, which are able to produce results within hours instead of days.
Widespread testing for the coronavirus is still unfeasible, Roche’s CEO Severin Schwan said in a press briefing on the coronavirus outbreak from industry leaders.
The FDA has approved Roche’s MRSA test, a technology that could give healthcare providers the ability to detect infections faster than traditional culture-based tests.
The pharma company Genfit has announced supportive data from a study involving a non-invasive algorithm driven blood test for the fatty liver disease known as NASH, a potential replacement
Imaging company Bracco is to buy Blue Earth Diagnostics for $450 million, netting £337 million for its owner Syncona, the UK’s largest listed life sciences investment firm.